News | March 20, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Experts urge early detection & better access to care
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
The European regulator will conduct a re-inspection of the facility to verify the compliance
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
Overall investment in the US facility is estimated around US$50 million
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
Subscribe To Our Newsletter & Stay Updated
